Giovale Massimo, Novelli Lucia, Persico Luca, Motta Francesca, Rampoldi Stefano, Galli Rossana, Monteforte Patrizia, Doveri Marica, Bianchi Gerolamo, Selmi Carlo, Bottaro Luigi Carlo
Division of Rheumatology, ASL3 Genovese, Genoa, Italy.
Rheumatology and Clinical Immunology; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Rheumatol Immunol Res. 2022 Jul 6;3(2):77-83. doi: 10.2478/rir-2022-0013. eCollection 2022 Jun.
Fibromyalgia symptoms have a significant impact on the quality of life and respond poorly to medications. It has been hypothesized that the use of low-energy pulsed electromagnetic field (PEMF) induces neuroprotective effects that may interfere with pain perception. We explored the efficacy of PEMF in patients affected by fibromyalgia.
Twenty-one females (median age 59 years, interquartile range [IQR] 16.5) affected by fibromyalgia were randomized to receive pulsed electromagnetic field-triple energy pain treatment (PEMF-TEPT) or placebo at T0 and at 4 weeks and 8 weeks. Fibromyalgia impact questionnaire (FIQ), widespread pain index (WPI), visual analog score (VAS) pain, symptom severity (SS) scale, and short form 36 (SF-36) health survey questionnaire have been evaluated.
Patients in the PEMF-TEPT group had a significantly higher reduction of WPI compared to placebo (mean difference -12.90 ± standard deviation [SD] 5.32 vs. -1.91 ± 4.55, difference in difference [DD] of -10.99; < 0.001), of SS score (-4.10 ± 4.85 vs. -2.00 ± 2.32; DD = -2.1; < 0.05), of VAS pain (-48 ± 30.75 vs. -16.82 ± 23.69; DD = -31.18; < 0.01). They also reported a higher improvement of FIQ and SF-36, albeit not reaching statistical significance.
In our pilot controlled study, PEMF-TEPT appeared to be safe and improved fibromyalgia symptoms.
纤维肌痛症状对生活质量有显著影响，且药物治疗效果不佳。据推测，低能量脉冲电磁场（PEMF）的使用可诱导神经保护作用，可能会干扰疼痛感知。我们探讨了PEMF对纤维肌痛患者的疗效。
21名受纤维肌痛影响的女性（中位年龄59岁，四分位间距[IQR]为16.5）被随机分配，在T0、4周和8周时接受脉冲电磁场 - 三重能量疼痛治疗（PEMF - TEPT）或安慰剂治疗。对纤维肌痛影响问卷（FIQ）、广泛性疼痛指数（WPI）、视觉模拟评分（VAS）疼痛、症状严重程度（SS）量表和简短健康调查问卷36（SF - 36）进行了评估。
与安慰剂相比，PEMF - TEPT组患者的WPI显著降低（平均差值 -12.90±标准差[SD]5.32 vs. -1.91±4.55，差值的差值[DD]为 -10.99；P<0.001），SS评分降低（-4.10±4.85 vs. -2.00±2.32；DD = -2.1；P<0.05），VAS疼痛降低（-48±30.75 vs. -16.82±23.69；DD = -31.18；P<0.01）。他们还报告了FIQ和SF - 36有更高的改善，尽管未达到统计学显著性。
在我们的试点对照研究中，PEMF - TEPT似乎是安全的，并改善了纤维肌痛症状。
